Kinaction (masitinib)

P2, N=72, Active, not recruiting, AB Science | Not yet recruiting --> Active, not recruiting

P2/3, N=145, Active, not recruiting, Ab Science | Recruiting --> Active, not recruiting

P3, N=140, Active, not recruiting, AB Science | Not yet recruiting --> Active, not recruiting

P2/3, N=135, Not yet recruiting, Ab Science

Tyrosine kinase inhibitors (TKIs), such as toceranib phosphate (Palladia) and masitinib, have demonstrated efficacy in MCTs...This review comprehensively synthesizes state-of-the-art literature on canine skin cancer, addressing pathophysiological mechanisms, diagnostic advancements, and emerging therapeutic strategies. In addition, this review aims to improve early detection, treatment outcomes, and enduring prognosis for affected canines by integrating recent findings into molecular oncology and comparative medicine.

P3, N=600, Not yet recruiting, AB Science | Trial completion date: Dec 2026 --> Dec 2029 | Trial primary completion date: Dec 2026 --> Dec 2028

P3, N=412, Not yet recruiting, AB Science

P3, N=495, Recruiting, AB Science | Trial completion date: Dec 2023 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2027

P3, N=800, Active, not recruiting, AB Science | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2028

Sunitinib, regorafenib, and ripretinib are currently approved as standard second-, third-, and fourth-line therapies, each demonstrating efficacy against distinct mutational profiles. Avapritinib, notably effective against PDGFRA D842V mutations, represents a milestone for previously untreatable subgroups. Several alternative agents-such as nilotinib, masitinib, sorafenib, dovitinib, pazopanib, and ponatinib-have shown varying degrees of success in refractory cases or specific genotypes. Investigational compounds, including crenolanib, bezuclastinib, famitinib, motesanib, midostaurin, IDRX-42, and olverembatinib, are under development to address resistant or wild-type GISTs...Future strategies include precision medicine approaches such as ctDNA-guided therapy, rational drug combinations, and novel drug delivery systems to optimize bioavailability and reduce toxicity. Ongoing research will be crucial for refining treatment sequencing and expanding therapeutic options, especially for rare GIST subtypes.

These findings demonstrate that masitinib, for the first time, attenuates sAD pathology through dual mechanisms of cognitive enhancement and neuroprotection. Our study provides strong preclinical evidence to support further clinical development of masitinib as a disease-modifying therapy for sAD.

Despite the considerable therapeutic progress in recent years, systemic mastocytosis is an incurable disease. In the last 20 years, the management of systemic mastocytosis has transformed from a one-size-fits-all approach, characterized by nonspecific cytoreductive drugs, to a tailored strategy focused on increasingly precise molecular targets, with the most notable example being the KIT inhibitors. Recently, the FDA and EMA have approved two drugs for treating systemic mastocytosis: avapritinib and midostaurin. Moreover, numerous trials are currently assessing the efficacy of new molecules: most are testing new-generation KIT inhibitors (ripretinib, bezuclastinib, elenestinib, masitinib, nintedanib), others focusing on Bruton's kinase (TL-895), interleukin-6 (sarilumab), sialic acid-binding immunoglobulin-like lectin-8 (lirentelimab), mTOR and CD33, among others. Real-life data are needed to confirm preliminary preclinical results.